Mary Linton Bounetheau Peters, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Pancreatic Ductal | 6 | 2022 | 1759 | 1.320 |
Why?
|
| Pancreatic Neoplasms | 9 | 2023 | 5446 | 1.250 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2023 | 66 | 0.820 |
Why?
|
| Financing, Organized | 1 | 2021 | 202 | 0.690 |
Why?
|
| Quarantine | 1 | 2021 | 186 | 0.620 |
Why?
|
| Germ Cells | 2 | 2019 | 644 | 0.600 |
Why?
|
| Research Support as Topic | 1 | 2021 | 697 | 0.560 |
Why?
|
| Research Personnel | 1 | 2021 | 589 | 0.540 |
Why?
|
| Mentors | 1 | 2021 | 672 | 0.520 |
Why?
|
| Genetic Counseling | 1 | 2019 | 635 | 0.480 |
Why?
|
| Genetic Testing | 4 | 2022 | 3591 | 0.440 |
Why?
|
| Infection Control | 1 | 2021 | 984 | 0.430 |
Why?
|
| Carcinoma in Situ | 1 | 2018 | 784 | 0.410 |
Why?
|
| Patients | 1 | 2019 | 908 | 0.400 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1907 | 0.370 |
Why?
|
| Family | 1 | 2019 | 3210 | 0.300 |
Why?
|
| Cholangiocarcinoma | 2 | 2023 | 561 | 0.290 |
Why?
|
| Bile Duct Neoplasms | 2 | 2023 | 614 | 0.290 |
Why?
|
| Biomedical Research | 1 | 2021 | 3464 | 0.260 |
Why?
|
| Germ-Line Mutation | 3 | 2019 | 1885 | 0.250 |
Why?
|
| Communication | 1 | 2019 | 3904 | 0.240 |
Why?
|
| Hepatitis C, Chronic | 2 | 2023 | 1032 | 0.230 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 6360 | 0.220 |
Why?
|
| Neoplasms | 2 | 2023 | 22350 | 0.210 |
Why?
|
| Hepatitis C | 2 | 2023 | 1594 | 0.200 |
Why?
|
| Gallbladder Neoplasms | 1 | 2023 | 190 | 0.190 |
Why?
|
| Polyps | 1 | 2023 | 200 | 0.190 |
Why?
|
| Albumins | 1 | 2023 | 577 | 0.170 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 4903 | 0.170 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2023 | 2330 | 0.170 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2019 | 86 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5389 | 0.150 |
Why?
|
| Deoxycytidine | 1 | 2023 | 886 | 0.150 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 793 | 0.150 |
Why?
|
| Organophosphorus Compounds | 1 | 2018 | 209 | 0.140 |
Why?
|
| Liver Neoplasms | 2 | 2023 | 4357 | 0.130 |
Why?
|
| Carbazoles | 1 | 2018 | 230 | 0.130 |
Why?
|
| Pancreas | 1 | 2023 | 1699 | 0.130 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 13491 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2023 | 1728 | 0.120 |
Why?
|
| Heterozygote | 1 | 2022 | 2794 | 0.120 |
Why?
|
| Truth Disclosure | 1 | 2019 | 434 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2022 | 18063 | 0.120 |
Why?
|
| Fluorouracil | 1 | 2019 | 1652 | 0.120 |
Why?
|
| Aged | 10 | 2023 | 171319 | 0.110 |
Why?
|
| Humans | 23 | 2023 | 767040 | 0.110 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 591 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 2 | 2023 | 5537 | 0.110 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 753 | 0.110 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2023 | 304 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2018 | 1248 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2023 | 2341 | 0.090 |
Why?
|
| Comorbidity | 3 | 2023 | 10582 | 0.090 |
Why?
|
| Mutation | 3 | 2023 | 30211 | 0.090 |
Why?
|
| Female | 12 | 2023 | 396660 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2023 | 4787 | 0.080 |
Why?
|
| Piperidines | 1 | 2018 | 1667 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 21178 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 3236 | 0.080 |
Why?
|
| Essential Tremor | 1 | 2011 | 160 | 0.080 |
Why?
|
| Male | 10 | 2023 | 364203 | 0.080 |
Why?
|
| Computer Simulation | 2 | 2019 | 6260 | 0.070 |
Why?
|
| Medicare | 2 | 2023 | 6813 | 0.070 |
Why?
|
| Middle Aged | 9 | 2023 | 223233 | 0.070 |
Why?
|
| Health Expenditures | 1 | 2019 | 2390 | 0.070 |
Why?
|
| Risk Factors | 3 | 2023 | 74886 | 0.070 |
Why?
|
| Incidence | 3 | 2023 | 21526 | 0.070 |
Why?
|
| United States | 4 | 2023 | 72971 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2018 | 3044 | 0.060 |
Why?
|
| Hepacivirus | 2 | 2023 | 1342 | 0.060 |
Why?
|
| Age Factors | 2 | 2019 | 18401 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2824 | 0.060 |
Why?
|
| Prevalence | 2 | 2019 | 15851 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 59548 | 0.050 |
Why?
|
| Deep Brain Stimulation | 1 | 2011 | 850 | 0.050 |
Why?
|
| Adult | 5 | 2022 | 223317 | 0.050 |
Why?
|
| Prognosis | 2 | 2023 | 29963 | 0.050 |
Why?
|
| Models, Biological | 1 | 2018 | 9464 | 0.050 |
Why?
|
| Liver Cirrhosis | 2 | 2023 | 1959 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11872 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 5693 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 292 | 0.050 |
Why?
|
| Disease Progression | 1 | 2018 | 13646 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2023 | 3070 | 0.040 |
Why?
|
| Models, Econometric | 1 | 2019 | 215 | 0.040 |
Why?
|
| Time Factors | 1 | 2021 | 40154 | 0.040 |
Why?
|
| Young Adult | 3 | 2023 | 59980 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2011 | 2886 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 12790 | 0.030 |
Why?
|
| Organoids | 1 | 2022 | 740 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 1444 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2018 | 65295 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2023 | 81659 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2023 | 6000 | 0.020 |
Why?
|
| Linear Models | 1 | 2019 | 5875 | 0.020 |
Why?
|
| Terminal Care | 1 | 2019 | 1770 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2022 | 54886 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 11217 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2019 | 22254 | 0.010 |
Why?
|
| Infant | 1 | 2023 | 36485 | 0.010 |
Why?
|
| Inpatients | 1 | 2011 | 2563 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2018 | 41718 | 0.010 |
Why?
|
| Adolescent | 1 | 2023 | 89046 | 0.010 |
Why?
|